Cancer cells have been shown to release aberrant glycan structures and glycoproteins in the bloodstream [5], where they can be detected and measured, particularly when tumour glycan epitopes involve tissue-specific proteins, such as aberrant circulating glycoforms of the prostate-specific antigen (PSA) in patients with prostate cancer [22]. Here, KLK3 is linked to neoplasm.